immunotherapy

Question 1

Ipilimumab

Answer 1

ctla4 inhibitor
ind: unresectable or mets melanoma
adj therapy who have cutaneous melanoma with regional melanoma
combination on trial wih nivolumab on nsclc, advanced rcc

Question 2

nivolumab

Answer 2

pd 1 inhibitor
single or with ipilimumab for unresectable or mets melanoma
nsclc following platinum based ct, following egfr or alk targered therapy
advanced renal.cell carcinoma following antiangiogenic therapy
classical hodgkin folowing autologus hsct and post transplant brentuximab vedoitin
recurrent or mets sq cell carcinoma of head and neck with disease progression or after platinum therapy

Question 3

pambrolizumab

Answer 3

unres or mets malignant melanoma
rec or mets hnsqcc
mets nsclc with positive tumor expression of pdl1

Question 4

durvalumab

Answer 4

pd1

locally advanced or mets urohelial carcinoma who have progressed following platinum basec tgerapy

Question 5

cancer vaccine

Answer 5

sipuleucel T

ind: treatment with minimally symptomatic metastatic castration resistant prostate cancer mcrpc

Question 6

how sipeuleucel t works

Answer 6

The patient undergoes leukopheresis to remove white blood cells, including antigen-presenting cells (APCs) • The APCs are exposed to a fusion protein antigen consisting of prostatic acid phosphatase (PAP) (expressed on 95% of prostate cancers) linked to granulocyte-macrophage colony-stimulating factor (GM-CSF) • Antigen is processed and presented on the surface of the APCs. GMCSF acts to help stimulate APC activity • The activated APC product is infused into the patient. Upon infusion, the activated APCs present the PAP antigen to T cells, leading to T-cell activation and proliferation toward prostate cancer cells expressing PAP